Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, Morgan Stanley said the agreement with a single, “reputable peptide manufacturer ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for ... of its dual GIP/GLP-1 agonist VK2735. Under the deal, CordenPharma will crank ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its investigational obesity drug, VK2735 ... the oral peptide should be ...

CordenPharma will provide large-scale manufacturing for VK2735 drug substance, and of fill-finish for the subcutaneous formulation and oral solid dosage manufacturing for the oral peptide formulation.

VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed in both oral and subcutaneous ...

The company's GIP/GLP-1 agonist, VK2735, appears undifferentiated, facing intense competition from existing and emerging obesity treatments. Plans to launch VK2735 with an auto-injector could ...

and more than one billion oral VK2735 tablets each year. “CordenPharma’s established presence in commercial peptide manufacturing gives us confidence in their ability to deliver supply ...

CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.